The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - A2 Healthcare; Amgen; Boehringer Ingelheim; Chugai Pharma; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; Noil-Immune Biotech; Oncolys BioPharma; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)
 
Antoine Adenis
Honoraria - BMS; MSD Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; Bayer Health; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre
Research Funding - Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pierre Fabre; SERVIER
 
Manish Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Peter Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; Henlius; IDEAYA Biosciences; ImmPACT Bio; Legend Biotech; Legend Biotech; Lilly; loxo; Loxo; Merck; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Regeneron; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Tatiane Ishida
Employment - Daiichi Sankyo
 
Leah Suttner
Employment - Bristol-Myers Squibb/Celgene (I); Merck
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene (I); Merck
 
Kanu Sharan
Employment - Medtronic (I); Merck
Leadership - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I); Merck
 
Pooja Bhagia
Employment - Merck
 
Jong-Mu Sun
Research Funding - bristol-myers squibb (Inst); pfizer (Inst); Yuhan (Inst)